Edwards Lifesciences Corp officer Daniel J. Lippis filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 1,857 shares of common stock through a cashless employee stock option exercise.

Key Highlights

  • Proposed sale: 1,857 shares of Edwards Lifesciences common stock with an aggregate market value of $193,592.00, according to the filing.
  • Acquisition method: Shares were acquired on November 10, 2026 via an employee stock option exercise, with payment described as a broker cashless exercise.
  • Approximate sale date: November 10, 2026, through broker Charles Schwab & Co., Inc., on the NYSE.
  • Shares outstanding: The filing reports 575,000,000 shares of common stock outstanding.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan was adopted on February 13, 2026, and notes that "the options on this filing may be sold over various dates."
  • Prior three-month sales: Lippis sold 619 shares on August 11, 2026 (gross proceeds $56,967.00), 619 shares on September 11, 2026 (gross proceeds $54,169.00), and 619 shares on October 8, 2026 (gross proceeds $53,017.00).

Lippis Form 144 Details: Stock Option Exercise and Proposed Sale

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Daniel J. Lippis, identified as an officer of Edwards Lifesciences Corp (NYSE:EW), proposed to sell 1,857 shares of the company's common stock. The filing lists the aggregate market value of these shares at $193,592.00. The shares were acquired through an employee stock option exercise on November 10, 2026, with the acquisition funded through a broker cashless exercise arrangement.

The filing discloses that Lippis adopted a written trading plan under Rule 10b5-1 on February 13, 2026, and the filing remarks that "the options on this filing may be sold over various dates." The proposed sale is to be executed through Charles Schwab & Co., Inc., located in Westlake, Texas, on the New York Stock Exchange.

As required by Form 144, the filing also discloses sales by Lippis during the prior three months. These consisted of three separate transactions of 619 shares each, sold on August 11, 2026, September 11, 2026, and October 8, 2026, generating gross proceeds of $56,967.00, $54,169.00, and $53,017.00, respectively, according to the filing.

What Was Disclosed

Edwards Lifesciences officer Daniel J. Lippis filed a Rule 144 notice proposing to sell 1,857 shares, valued at $193,592.00, obtained through a cashless stock option exercise on November 10, 2026, under a 10b5-1 plan adopted February 13, 2026.